Drug intelligence / Profile preview

Xolatryp

Development stage: Phase 2
Lead developer: Nyrada
Modality: Small Molecules
Administration: Intravenous

Overview

**Xolatryp** (formerly NYR-BI03) is a first-in-class small-molecule inhibitor of Transient Receptor Potential Canonical (TRPC) ion channels developed by Nyrada Inc. for neuroprotection and cardioprotection. It limits pathological calcium ion entry into cells, stabilizes mitochondrial function, reduces reactive oxygen species damage, and mitigates secondary injury in conditions like ischemic stroke, traumatic brain injury (TBI), and myocardial ischemia-reperfusion injury (MIRI). Preclinical studies have demonstrated significant efficacy, including 42% rescue of brain tissue in stroke models and preservation of mitochondrial health in penetrating TBI models.[4][6][8][12]

Brand names: Xolatryp

Targets

TRPC7TRPC3

Beyond the preview

Go deeper on Xolatryp.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xolatryp.

Explore the full profile